What is AVEO Pharmaceuticals Profitability Rank?
AVEO Pharmaceuticals has the Profitability Rank of 3. It has had trouble to make a profit.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:
1.
Operating Margin %
2.
Piotroski F-Score
3. Trend of the
Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank
AVEO Pharmaceuticals's Operating Margin % for the quarter that ended in Sep. 2022 was -7.12%. As of today, AVEO Pharmaceuticals's Piotroski F-Score is 4.
Competitive Comparison of AVEO Pharmaceuticals's Profitability Rank
For the Biotechnology subindustry, AVEO Pharmaceuticals's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AVEO Pharmaceuticals's Profitability Rank Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AVEO Pharmaceuticals's Profitability Rank distribution charts can be found below:
* The bar in red indicates where AVEO Pharmaceuticals's Profitability Rank falls into.
AVEO Pharmaceuticals Profitability Rank Calculation
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.
AVEO Pharmaceuticals has the Profitability Rank of 3. It has had trouble to make a profit.
Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.
Profitability Rank is based on these factors:
1. Operating Margin %
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
AVEO Pharmaceuticals's Operating Margin % for the quarter that ended in Sep. 2022 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
2. Piotroski F-Score
The zones of discrimination were as such:
Good or high score = 8 or 9
Bad or low score = 0 or 1
AVEO Pharmaceuticals has an F-score of 4 indicating the company's financial situation is typical for a stable company.
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
Good Sign:
AVEO Pharmaceuticals Inc operating margin is expanding. Margin expansion is usually a good sign.
4. Consistency of the profitability
5. Predictability Rank
AVEO Pharmaceuticals (AVEO Pharmaceuticals) Business Description
Traded in Other Exchanges
N/A
Address
30 Winter Street, Boston, MA, USA, 02108
AVEO Pharmaceuticals Inc is a commercial-stage, oncology-focused biopharmaceutical company engaged in offering medicines that provide a better life for patients with cancer. The company markets FOTIVDA (tivozanib) in the United States. FOTIVDA is an oral, next-generation vascular endothelial growth factor receptor, or VEGFR, tyrosine kinase inhibitor, or TKI. The group primarily operates in the U.S.
Executives
| Jebediah Ledell |
officer: Chief Operating Officer |
C/O AVEO PHARMACEUTICALS, INC., 30 WINTER STREET, BOSTON MA 02108 |
| Michael P Bailey |
director, officer: President & CEO |
IMCLONE SYSTEMS INCORPORATED, 180 VARICK STREET, 6TH FLOOR, NEW YORK NY 10014 |
| Michael Ferraresso |
officer: Chief Commercial Officer |
AVEO PHARMACEUTICALS, INC., 30 WINTER STREET, BOSTON MA 02108 |
| Kevin Joseph Cullen |
director |
AVEO PHARMACEUTICALS, INC., 30 WINTER STREET, BOSTON MA 02108 |
| Epperly Corinne |
director |
AVEO PHARMACEUTICALS, INC., 30 WINTER STREET, BOSTON MA 02108 |
| Peter W. Sonsini |
10 percent owner |
2855 SAND HILL ROAD, MENLO PARK CA 94025 |
| Florence Anthony A. Jr. |
10 percent owner |
5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815 |
| Forest Baskett |
10 percent owner |
|
| Joshua Makower |
10 percent owner |
1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043 |
| Scott D Sandell |
10 percent owner |
|
| Growth Equity Opportunities Iv, Llc |
10 percent owner |
1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093 |
| Mohamad Makhzoumi |
10 percent owner |
2855 SAND HILL ROAD, MENLO PARK CA 94025 |
| Erick Lucera |
officer: Chief Financial Officer |
138 THISTLE ROAD, NORTH ANDOVER MA 08145 |
| Scarlett Spring |
director |
AVEO PHARMACEUTICALS, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142 |
| Peter J Barris |
10 percent owner |
1119 ST PAUL STREET, BALTIMORE MD 21202 |
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AVEO has been successfully added to your